# Tesamorelin

> GHRH analog FDA-approved for HIV-associated lipodystrophy.

- Also known as: Egrifta
- Class: Growth Hormone, Metabolic
- FDA approved: Yes
- Canonical page: https://www.americanpeptide.com/catalog/tesamorelin

## Overview

Tesamorelin is a stabilized 44-amino-acid GHRH analog approved by the FDA in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Tesamorelin is a stabilized 44-amino-acid analog of growth-hormone-releasing hormone (GHRH). By stimulating the pituitary to release endogenous GH, it preserves more of the body’s natural feedback than exogenous GH would.

It is FDA-approved (Egrifta, 2010) specifically to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy. Beyond that indication it has been studied for visceral adiposity more broadly and, in research settings, for effects on cognition.

## Mechanism

GHRH receptor agonism → endogenous GH release.

## Chemistry

| Property | Value |
| --- | --- |
| Molecular formula | C221H366N72O67S |
| Molecular weight | 5135.9 Da |
| CAS number | 218949-48-5 |
| PubChem CID | [16137828](https://pubchem.ncbi.nlm.nih.gov/compound/16137828) |

## Research areas

Studied in: Visceral adiposity, HIV-associated lipodystrophy, Cognition.

Guides on this site:

- [Weight Loss & Metabolic Health](https://www.americanpeptide.com/research-areas/weight-loss): Incretin and metabolic peptides studied for glycemic control and fat loss.
- [Cognition & Neuroprotection](https://www.americanpeptide.com/research-areas/cognition-neuroprotection): Nootropic and neurotrophic peptides studied for cognition and recovery.

## Key research

- Visceral fat reduction — the approved use, lowering excess abdominal fat in HIV-associated lipodystrophy.
- GH axis — GHRH-receptor agonism raising endogenous GH and IGF-1.
- Cognition — examined in research for effects related to GH signaling.
- Hepatic fat — studied as a metabolic endpoint.
- FDA-approved (Egrifta) — for a specific HIV-related indication.

## FAQs

### What is tesamorelin?

Tesamorelin is a GHRH analog FDA-approved (Egrifta) to reduce excess abdominal fat in people with HIV-associated lipodystrophy.

### How does it work?

It stimulates the pituitary to release the body’s own growth hormone, rather than supplying GH directly.

### What is it approved for?

Reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Other uses described here are research contexts, not approved indications.

### Is this medical advice?

No — this page is a research and educational reference, not medical advice or a dosing protocol.

## Latest research

Recent trials and publications mentioning Tesamorelin, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily).

### Recent trials

- [Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV](https://clinicaltrials.gov/study/NCT06554717) — RECRUITING · PHASE2 · NCT06554717
- [Body Composition and Adipose Tissue in HIV](https://clinicaltrials.gov/study/NCT03226821) — TERMINATED · PHASE4 · NCT03226821
- [Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)](https://clinicaltrials.gov/study/NCT07481734) — RECRUITING · PHASE2 · NCT07481734
- [Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons](https://clinicaltrials.gov/study/NCT02572323) — COMPLETED · PHASE2 · NCT02572323
- [Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk](https://clinicaltrials.gov/study/NCT03375788) — COMPLETED · PHASE2 · NCT03375788
- [Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury](https://clinicaltrials.gov/study/NCT03150511) — RECRUITING · PHASE2 · NCT03150511

---

Source: AmericanPeptide.com — https://www.americanpeptide.com/catalog/tesamorelin
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.